Glucagon and Amylin Biology
What the body's own hormones glucagon and amylin do, how they relate to GLP-1, and how this biology differs from the medicines and research compounds built on them.
Content last updated . This page has not been medically reviewed.
Evidence labels: established (well described physiology), preclinical (cells/animals only), insufficient evidence.
Glucagon
- Where it comes from. Glucagon is made by alpha cells of the pancreatic islets from the preproglucagon gene. The same gene gives rise to GLP-1, GLP-2, oxyntomodulin and glicentin in gut cells. [1]
- Main job. Glucagon is established mainly as a counterregulatory hormone: it rises when blood sugar is threatened and drives glucose production to restore normal levels. [1]
- Wider roles. Pharmacology studies suggest a possible role in energy expenditure. [1] Reviews also describe effects on lipids, body weight and vascular health, and note that glucagon biology has been re-examined in recent years. [2] Label: mixed, still being worked out.
- Cross-talk. GLP-1 inhibits glucagon secretion, so these related peptides influence each other. [1]
Amylin
- What it is. Amylin, also called islet amyloid polypeptide, is made in pancreatic beta cells and released with insulin after nutrients. [3]
- What it does. It acts as a physiological signal that ends a meal, limits the rate of gastric emptying and reduces glucagon secretion after eating. [3]
- Where it acts. Effects are mediated by direct brain activation, with the caudal hindbrain playing the biggest part. Amylin receptors combine a calcitonin core receptor with accessory proteins. [3]
- Link with leptin. Amylin has been found to sensitize the body to leptin's effects, so far discussed as a mechanism. [3]
Biology versus medicines
| Natural hormone | Medicine or compound | |
|---|---|---|
| Amylin | Endogenous pancreatic hormone [3] | Pramlintide, an amylin mimetic, was approved by the FDA in 2005 for type 1 diabetes and insulin-requiring type 2 diabetes [4] |
| Glucagon | Endogenous pancreatic hormone [1] | Stable, water-soluble glucagon analogues have been made for study, and glucagon activity is now part of some weight-treatment research [2] |
Pramlintide is based on the structure of rat amylin rather than being identical to human amylin. [5]
What the research does not show
Efforts to develop an amylin-based anti-obesity medicine stalled in the past because of dosing frequency, safety and formulation challenges, and newer amylin-based molecules are described as nearing approval, not yet established. [4] The same review raises questions about loss of lean body mass with GLP-1 therapies and the regulatory and ethical questions of treating otherwise healthy people with overweight. [4] We did not find usable evidence in this library's sources to compare any amylin product with another.Where to go next
- How these hormones fit with appetite and the stomach: satiety and gastric emptying signaling
- The gut hormones made from the same gene family: GLP-1 and GIP biology
- Weight and metabolic questions in everyday terms: obesity and weight-related health
Frequently asked questions
What is the difference between glucagon and GLP-1?
Both come from the same gene, but glucagon is made mainly by pancreatic alpha cells and raises glucose output, while GLP-1 is made in the gut and improves glucose handling, partly by lowering glucagon secretion. [1]
Does amylin help end a meal?
Yes, it is described as a physiological control of meal-ending satiation. [3]
Is amylin the same as pramlintide?
No. Pramlintide is a drug designed from amylin's structure; amylin is the natural hormone. [5]
Are there approved amylin-based medicines for obesity?
The review we read says anti-obesity amylin therapeutics were stalled and newer molecules were nearing approval as of its 2025 publication. We did not verify any regulator's current decision. [4]
Does higher glucagon mean better metabolism?
No. Glucagon is a regulating signal with different effects in different settings, and no source we read treats higher levels as a goal. [2]
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
Safety note
References
- Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiological Reviews 2015. Read 2026-10-22.
- The New Biology and Pharmacology of Glucagon. Physiological Reviews 2017. Read 2026-10-22.
- Mediators of Amylin Action in Metabolic Control. Journal of Clinical Medicine 2022. Read 2026-10-22.
- Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus. Nature Reviews Endocrinology 2025. Read 2026-10-22.
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. Peptides 2026. Read 2026-10-22.